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Cardiac channelopathies are rare genetic disorders associated with an increased risk of 
ventricular arrhythmia and sudden death, often in previously asymptomatic and ostensibly 
healthy young individuals with a structurally normal heart. This article aims: (a) to review 
the clinical characteristics and genetic basis of common cardiac ion-channel diseases, (b) 
to highlight some of the genotype-phenotype correlations available to date, and (c) to sum-




Since the completion of the Human Genome Project in 2003, a revolutionary technological 
development has taken place in genomics, the science that evolved from genetics, molec-
ular biology, and bioinformatics. Rapid advances in genotyping methods, characterised by 
miniaturisation and automation and high-throughput analysis of DNA, have reduced the 
cost and time and increased the accuracy of DNA sequencing. Another great impact of 
next-generation sequencing and array-based technologies has been the ability to investi-
gate biological phenomena in a more complex manner, at the level not only of the ge-
nome, but also the epigenome, proteome, and metabolome, in a comprehensive, and un-
biased manner (Schwartz AL, 2011). This has reshaped our view of genome physiology, 
and also deepened our understanding of genetics in familial and potentially lethal cardio-
vascular diseases, such as cardiac channelopathies. Technological advances in genotyp-
ing, on the other hand, have also provided an enormous amount of data and resulted in a 
discrepancy between data generation and the linkage of data to clinical significance. This 
has made integration of genomic information into clinical practice challenging, particularly 
in the case of rare diseases. 
 
Clinical features of cardiac ion channel disease 
Cardiac channelopathies are rare genetic disorders associated with an increased risk of 
ventricular arrhythmia and sudden death, often in previously asymptomatic and ostensibly 
healthy young individuals with a structurally normal heart. They include long QT syndrome 
(LQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular tachy-
cardia (CPVT), as well as other rarer types, such as short QT syndrome (SQTS), early re-
polarisation syndrome, progressive cardiac conduction disease (PCCD), and multifocal ec-
topic Purkinje-related premature contractions.  
 
Long QT syndrome  
LQTS is characterised by QT prolongation and abnormal T-wave morphology on the sur-
face ECG (Fig.1.), and is associated with syncope and sudden death caused by torsades 
  
de pointes  (TdP) and ventricular fibrillation (VF). The estimated prevalence is 1:2000, with 
a mean age at presentation of 14 years. The diagnosis is made on the basis of a heart 
rate-corrected QT interval (QTc) ≥ 480ms on repeated ECGs or a LQTS risk score > 3 
(Table 1.). The diagnosis can also be made in the presence of unexplained syncope with 
no secondary causes for QT prolongation and a QTc ≥ 460ms (Priori SG et al, 2015). In 
25-40% of patients the QT intervals may be non-diagnostic at rest, which makes diagnosis 
of LQTS challenging. In these ‘concealed' cases additional investigations, including exer-
cise testing, adrenaline challenge and Holter monitoring, may increase diagnostic sensitiv-
ity. Additional electrocardiographic features include T wave alternans, prominent U waves 
and T-U complexes and bradycardia, which may present as either sinus bradycardia, or 
functional 2:1 AV block when QT interval is very long. Symptoms are often precipitated by 
adrenergic activation, e.g. physical activity or emotional stress, but may also occur at rest 
or during sleep. The incidence of syncope is estimated to be 5% per year, whereas the an-
nual rate of sudden death is reported to be between 0.33 and 0.9% in untreated individu-
als. Some forms of LQTS are associated with extra-cardiac manifestations, such as con-
genital deafness in Jervell and Lange-Nielsen syndrome, syndactyly in Timothy syndrome 




Fig. 1. Characteristic ECGs in long QT syndrome. 
A) LQT1 - ECG of a 10 year-old boy with a KCNQ1 mutation and recurrent syncope on exertion, show-
ing broad-based T waves. 
B) LQT2 - ECG of a 10 year-old boy with a familial KCNH2 mutation, showing low voltage, notched T 
waves. 
C) LQT3 - ECGs of a 14 year-old boy with recurrent Torsades des Pointes (TdP) despite medical ther-
apy, fitted with an ICD. 12-lead ECG shows atrial pacing with extreme QT prolongation, character-
ised by a  long isoelectric ST segment and symmetrical T waves (above); rhythm strip demonstrates 
TdP ventricular tachycardia (below). 
 
Brugada syndrome 
BrS is a clinical entity with a characteristic pattern of J point and ST segment elevation in 
the right precordial leads of a 12-lead ECG, associated with risk of fatal arrhythmic events. 
Conduction delays at various cardiac levels are also commonly seen. The prevalence 
ranges from 1:1000 to 1:10,000, with a seemingly higher occurrence in South-East Asian 
populations (Fowler SJ and Priori SG, 2009). Clinical manifestations are more frequent in 
adults with a mean age of 41 ± 15 years at presentation and a male predominance. The 
resting ECG can be completely normal, but fever, excessive alcohol intake and large 
meals may unmask the typical Brugada ECG pattern. The annual rate of arrhythmic 
events, including sustained VT, VF and sudden death, is 13.5% in patients with a history 
of aborted cardiac arrest, 3.2% in patients with syncope and 1% in asymptomatic patients, 
respectively (Fauchier L et al, 2013). The diagnosis is based on ST-segment elevation with 
type 1 morphology ≥2mm (Fig. 2.) in one or more, conventionally placed or high right pre-
cordial leads, occurring spontaneously or induced by sodium channel blockers (e.g. ajma-





Fig. 2. Characteristic ECG in Brugada syndrome. 
Positive Ajmaline challenge test in a 13 year-old boy with a family history of Brugada syndrome, showing 
cove-shaped ST segment elevation and T wave inversion in the right ventricular precordial leads. ECG 
tracings from the high right precordial leads (2nd intercostal space) are shown in V5 and V6 position.  
 
Catecholaminergic polymorphic ventricular tachycardia 
The main feature of CPVT is bidirectional or polymorphic VT and VF (Fig. 3.) precipitated 
by a sudden increase in sympathetic tone, such as physical exercise or emotional stress. 
The prevalence is estimated to be 1:10,000 (Priori SG et al, 2013). The first symptoms 
usually present within the first decade of life with a mean age of 7-9 years, but later onset 
has also been reported (Hayashi M et al, 2009).The resting ECG is typically normal with 
the occasional presence of subtle sinus bradycardia. An exercise stress test is generally 
diagnostic with the onset of premature bidirectional or polymorphic ventricular ectopics as 
  
the heart rate approaches 120 beats/min, but in some cases it remains negative. An 
adrenaline challenge test has been suggested to increase the sensitivity of diagnosis. 
 
 
Fig. 3. Characteristic ECG in catecholaminergic polymorphic ventricular tachycardia. 
Exercise test in an 11 year-old boy with recurrent syncope on exertion showing polymorphic ventricular 
ectopics and bidirectional ventricular tachycardia. 
 
Other cardiac channelopathies  
Short QT syndrome is a recently described channelopathy characterised by reduced 
length of cardiac repolarisation. QTc interval ≤ 340ms is diagnostic, but SQTS can also be 
considered if the QTc ≤ 360ms in the presence of a pathogenic mutation or after an epi-
sode of otherwise unexplained VT/VF arrest, or when the family history is positive for 
SQTS or for sudden cardiac death at a young age (Priori SG et al, 2015). In addition to the 
shortened QT interval, tall and peaked T-waves with almost absent ST-segments appear 
to be characteristic in some types of SQTS. 
Early repolarisation syndrome is another rare condition associated with idiopathic VF. The 
pattern of early repolarisation described as J point elevation ≥0.1 mV in two adjacent leads 
with either slurred or notched terminal QRS morphology has been considered as a normal 
ECG variant. It has been seen especially frequently in athletes and young individuals and 
at slower heart rates, with an overall prevalence of 5-13% in the general population. How-
ever, recent studies of idiopathic VF have suggested an association of the pattern with in-
creased risk of arrhythmic deaths (Haissaguerre M et al, 2008). Early repolarisation syn-
drome is characterised by the presence of a typical ECG pattern in the context of an other-
wise idiopathic VF arrest. 
 
Genetic basis of cardiac channelopathies 
Cardiac ion channels (Table 2.) mediate precisely regulated movements of ions conducted 
through the cell membrane, thereby playing a crucial role in the normal generation and 
propagation of the action potential of myocardial cells (Fig. 4.). An imbalance of inward 
and outward currents, mainly affecting repolarisation of myocytes, alters the spatio-tem-
poral pattern of repolarisation within the myocardium and creates a substrate for electro-
physiological heterogeneity. This predisposes to the development of ventricular tach-
yarrhythmias that represent the common clinical endpoint of the different cardiac chan-
nelopathies. Abnormal ionic changes are primarily caused by mutations in one or more 
genes encoding ion channels, cytoskeletal anchoring proteins or components of caveolae. 
Whilst cardiac channelopathies have been considered to be monogenic disorders, in order 
  
to understand the phenotype of these conditions the function of the whole biological sys-
tem that effects repolarisation needs to be considered. 
Fig. 4. Major ionic currents of the myocardial action potential. 
Phase 0: inward Na+ current (INa), rapid depolarisation. 
Phase 1: transient outward K+ current (Ito), early repolarisation, ‘notch’. 
Phase 2: balance between the inward depolarising Ca2+ and the outward delayed rectifier   
                                           K+ currents (IKr, IKs), repolarisation ‘plateau’. 
Phase 3: inactivation of inward current and increase of outward currents (IKr , IKs , IK1). 
Phase 4: membrane potential returns to its resting potential. 
 
Genes and genetic heterogeneity. 
Since the description of the first cardiac channelopathy causative genes in 1995, a large 
number of distinct genes with hundreds of mutations have been associated with inheritable 
channelopathies (Table 3.). Mutations usually cluster in families, or may occur sporadi-
cally. They are most commonly inherited as autosomal dominant traits, but autosomal re-
cessive inheritance can also occur.  
The genetic basis of long QT syndrome can be identified in 75-80% of cases (Ackerman 
MJ et al, 2011). Currently, mutations in at least 15 genes have been linked to LQTS, most 
of which encode voltage-gated potassium, sodium and calcium channels. The majority of 
mutations cause loss-of-function; however, some result in enhanced activity, as seen in 
LQT3 or Timothy syndrome. The most common disease-causing genes are KCNQ1, 
KCNH2 and SCN5A, accounting for 90% of positively genotyped cases. Certain rare muta-
tions in the KCNQ1 gene, and also in KCNE1 gene, cause Jervell and Lange-Nielsen syn-
drome: a unique, autosomally recessively inherited form of LQTS characterised by ex-
treme QT prolongation, severe to profound congenital deafness and vestibular dysfunc-
tion. 
In contrast to the relative high yield from genetic testing in LQTS, the genetic cause of Bru-
gada syndrome is only identified in approximately 25% of cases. The genetic background 
of the condition is very complex and heterogeneous and still not completely understood, 
with at least 16 genes causally related. Many of these genes play a role in the pathogene-
sis of other channelopathies, too, thereby creating ‘overlap syndromes’ or ‘mixed pheno-
types’ that share features of both BrS and other channelopathies (e.g., SQTS or PCCD). 
  
Only two genes, SCN5A and CACN1AC, account for >5% of positively genotyped individu-
als with BrS (Wilde AA and Behr EE, 2013), with SCN5A mutations accounting for 20-30% 
of cases (Kapplinger DJ et al, 2010), while the contribution of other genes is less frequent. 
Genetic confirmation of CPVT is achievable in about 60-70% of patients. Mutations in the 
cardiac ryanodine receptor 2 gene (RYR2), inherited as an autosomal dominant trait, are 
found in 55-65% of affected individuals (Ackerman MJ et al, 2011) whereas pathological 
variants of calsequestrin gene (CASQ2), autosomally recessively inherited, account for 1-
2% of the cases (Ackerman MJ, Marcou CA and Tester DJ, 2013). Mutations in other 
genes are also implicated in CPVT, but at present it is not clear whether they are part of 
the same spectrum of disease or represent phenocopies. 
There is substantial genetic heterogeneity, with different mutations in the same cardiac ion 
channel genes resulting in different phenotypes, depending on their functional effect. For 
example, gain-of-function mutations in SCN5A gene cause LQT3 syndrome, while loss-of-
function mutations may be responsible for BrS, familial atrial fibrillation, PCCD and sick si-
nus syndrome. Similarly, K+ channel mutations can delay repolarisation (LQTS), lead to 
Andersen-Tawil syndrome (LQT7), speed up repolarisation (SQTS), or trigger atrial fibrilla-
tion. Abnormal changes in intracellular Ca2+ handling can cause Timothy syndrome 
(LQT8), BrS, SQTS and CPVT.  
 
Clinical heterogeneity 
The clinical heterogeneity of channelopathies is not only a consequence of the involve-
ment of various genes with multiple mutations in pathogenesis. The manifestation of dis-
ease may vary significantly, even in the case of the very same pathological variant of a 
gene, from silent carrier state to SCD. This is caused by the incomplete penetrance and 
variable expressivity of these conditions. CPVT is a highly penetrant channelopathy with 
early manifestation compared to Brugada syndrome, which has a generally low, age and 
sex-related penetrance with later onset of symptoms, predominantly in males. Although 
the exact mode of action from a systems biology perspective is poorly understood, several 
genetic and epigenetic factors are known to influence gene expression. For example, poly-
morphisms, either within established susceptibility genes for channelopathies or in genes 
that modulate cardiac ion-channel function through transcriptional or post-translational ef-
fects, may modify disease penetrance and expression (Giudicessi JR and Ackerman MJ, 
2013). Furthermore, compound or digenic heterozygosity, when two different mutations 
are found either on the same alleles of a chromosome pair or in two different disease-as-
sociated genes, can be associated with earlier and more severe disease expression. In 
multigenerational pedigrees, 4-8% of LQTS probands were found to harbour a second in-
dependent disease-causative mutation. 
Other candidate modifiers have been postulated, some of which participate in autonomic 
responses (Schwartz PJ et al, 2013) and some are determinants of the repolarisation re-
serve (Varro A and Baczko I, 2011). Individual differences in autonomic tone, and in the 
  
magnitude of catecholaminergic response to stress, and also in the capacity to compen-
sate for functional or inherited impairment of repolarisation currents, are known to influ-
ence susceptibility to triggered arrhythmia. Genetic determinants of these factors may well 
contribute to the expression of a certain ion channel disease. 
 
Repolarisation reserve 
The cardiac repolarisation process is governed by interactions of multiple ion channels and 
their regulators. Any alteration in the function of an individual component, through genetic 
or acquired mechanisms, can modulate repolarisation and allow changes that elicit sus-
ceptibility to ventricular arrhythmia. On the other hand, there is also a degree of redun-
dancy in the system that enables it also to tolerate alterations to a certain degree. This 
‘buffer-capacity’ is known as the repolarisation reserve and represents a functional com-
pensatory mechanism for the loss of a single ionic component (e.g. up-regulation of IKs 
when IKr is reduced). However, if the repolarisation reserve is reduced, a change in a sin-
gle current may be poorly tolerated. This occurs if a compensatory mechanism is attenu-
ated by a drug or affected by a subclinical mutation per se, but bradycardia, hypokalaemia, 
gender, and underlying cardiac pathology are also known factors that interact and deter-
mine repolarisation reserve capacity (Xiao L et al, 2008). The concept originally suggested 
a static nature for the relationship between the main ionic current, IKr determining repolari-
sation and other ionic components (IKs, INa,L) that provide reserve against IKr  inhibition. 
More recent data, however, have suggested a more dynamic interaction (Roden DM, 
2008), and involvement of various ionic mechanisms (e.g. inward sarcolemmal sodium-cal-
cium exchanger current (INCX), as well as hyperpolarization activity current (If), which con-




While determinants of heterogeneity in the channelopathies remain incompletely under-
stood, several important associations between genotype and arrhythmic risk and demo-
graphic features and electrocardiographic phenotype have been elucidated. In LQTS in 
particular, these correlations may carry diagnostic, prognostic and therapeutic implications, 
underpinning the importance of genotyping.  
Patients with LQT1 typically have broad-based T waves with a delayed upstroke on the 
surface ECG. They may also show paradoxical lengthening of the QT interval in response 
to sympathetic stimulation; QT prolongation during exercise is even greater with pore re-
gion mutations than with non-pore mutations, associated with a greater risk of exercise-
triggered cardiac events (Jons C et al, 2009). In childhood, males have also been found to 
have a higher risk for developing arrhythmia. Arrhythmic events are likely to occur on exer-
cise, particularly during swimming. Patients respond very well to β-blocker therapy with no 
apparent shortening of the QTc interval at rest, but a decrease in the number of cardiac 
events (Priori et al, 2003). 
  
LQT2 patients tend to show low-amplitude and notched or bifid T wave morphology on 
resting ECG. There is a phase-specific QT-T response on exercise with only an initial out-
of-proportion QT prolongation and a more prominent appearance of the flat and bifid re-
polarisation pattern, followed by appropriate shortening of the QTc interval. The arrhythmic 
trigger is often a sudden auditory or emotional stimulus. Women during the 9-month post-
partum period have an especially high risk of arrhythmia. Patients with transmembrane 
pore region mutations show a longer QT interval and experience more arrhythmic events 
at a younger age than those with frame-shift or nonsense mutations affecting any other re-
gion of the HERG channel. Missense mutations affecting the C-terminus of Kv11.1 are as-
sociated with the lowest risk for cardiac events. (Shimizu W et al, 2009) 
In LQT3 syndrome long isoelectric ST segments are followed by short symmetrical T 
waves on the surface ECG. The QT interval shortens appropriately on exercise, and ar-
rhythmic events tend to occur during sleep or at rest. Patients have a higher incidence of 
lethal cardiac events than those with LQT1 or LQT2. Response to β-blocker therapy is less 
effective than in LQT1, but targeting the excessive late sodium current, which is a result of 
the gain-of-function mutation of the sodium channel, with inhibitory agents such as mex-
iletine, may provide a more gene-specific therapy (Shimizu W, 2008).  
Other channelopathies possess less well-established genotype-phenotype correlations. In 
CPVT, early onset of disease has been associated with RYR2 mutations, and male carri-
ers in particular have been found to have a fourfold increased risk of cardiac events com-
pared to female carriers (Priori SG et al, 2002).  
 
 
Genetic testing for primary arrhythmia syndromes in clinical practice 
Comprehensive or targeted genetic testing is recommended for patients with a strong clini-
cal suspicion of LQTS or CPVT, and represents a class I indication. Given the lower yield 
of genetic testing in BrS and other channelopathies, testing of patients with high suspicion 
of the specific condition may be useful, as a class II indication. Following the identification 
of a disease-causing mutation in a proband, mutation-specific predictive genetic testing is 
recommended for first degree relatives (Ackerman MJ et al, 2011). 
Targeted post-mortem genetic analysis should be considered in all sudden death victims in 
whom an inheritable channelopathy is suspected (Priori SG et al, 2015). This, so-called 
molecular autopsy is able to identify a post-mortem diagnosis of heritable cardiac chan-
nelopathy in 15-20% of cases. Moreover, comprehensive clinical cardiological screening of 
first-degree relatives of a SADS victim results in the diagnosis of an ion channel disorder, 
most commonly  LQTS, BrS and CPVT, in up to 50% of cases, including paediatric rela-
tives (Guidici et al, 2014). 
  
Interpretation of results of genetic testing for inheritable cardiac channelopathies  
  
In the era of high-throughput DNA analysis several genetic variants are identified and clas-
sifying these as disease-causing or normal variants is crucial, but may be very challenging 
and requires expertise. Variants found in individuals with ion channel disease are usually 
non-synonymous single nucleotide substitutions. These may cause a single change in the 
amino acid sequence of the encoded protein (missense mutation), or result in its truncation 
by a premature stop codon (nonsense mutation). Generally, it is easier to classify a novel 
nonsense variant as pathogenic. However, if a novel missense variation  segregates with 
disease status in a family, is clearly absent from a control population, is located in a highly 
conserved amino acid sequence, and/or changes the physico-chemical property of the 
protein significantly it may well be considered as potentially disease-causing. In silico and 
in vitro tools are also available for helping to predict the functional effect of a variant. If de-
spite all considerations a novel variant remains unclassified the term ‘sequence variation 
of unknown/uncertain significance’ (VUS) is used. These have limited value in confirming a 
clinical diagnosis and cannot be solely used for identifying at-risk relatives. However, their 
presence as a second variant may modify disease expression.  
The pathogenic mutation:VUS ratio is the ‘signal-to-noise‘ ratio of the genetic test and rep-
resents its positive predictive value. It is highly disease-dependent, being approximately 
20:1 in CPVT and LQTS; that means a relatively low rate of false positivity compared to a 
less desirable ratio of 10:1 for BrS (Ackerman MJ et al, 2011). Conversely, in cardiac 
channelopathies a negative test result in a clinically affected individual does not rule out 
disease, especially in syndromes with a low yield from genetic testing, such as BrS or 
SQTS. 
 
Ethical aspects of genetic testing in ion channel disease 
Predictive testing in clinically unaffected family members can help to elucidate disease sta-
tus and inheritance risk. Given the clinical heterogeneity of channelopathies, predictive ge-
netic testing as part of the clinical screening helps to identify relatives at risk. In some 
cases, such as LQTS and CPVT, prophylactic treatment and life-style modification may be 
recommended. However, predictive testing may also have implications in terms of partici-
pation in sports, employment and life insurance (Ingles et al, 2011). Genetic counselling is 
therefore extremely important pre- and post-testing, as both positive and negative results 
may carry significant clinical and psychosocial impacts that need to be addressed in detail, 
and should be carried out in the setting of an expert inherited cardiovascular diseases ser-
vice. The ‘right not to know’ and the possibility to decline molecular screening should be 
included in the communication with the relatives.  
Predictive genetic testing in children is a particularly complex issue that should be man-
aged on a case-by-case basis. In some of the inherited cardiovascular diseases, such as 
some of the later-onset cardiomyopathies, postponing testing to an older age with a better 
understanding may be advisable. However, for most of the inheritable channelopathies 
(e.g., LQTS, CPVT) pre-symptomatic testing can be performed earlier in life, given that 
sudden death may occur at any age, but the risk of an arrhythmic event can be signifi-







The diagnostic, prognostic and therapeutic implications of genetic testing in cardiac chan-
nelopathies are very much disease-dependent. Given the genetic and clinical heterogene-
ity of these rare conditions the current yield from genetic testing in confirming clinical diag-
nosis varies from 20% for BrS and SQTS to 75-80% for LQTS. Its diagnostic impact is rea-
sonably well-established in LQTS and CPVT compared to BrS, but the effect on prognosis 
and therapy is only valuable in LQTS at present. However, once a disease-causing muta-
tion is identified it does have further value in identifying silent carriers or at-risk relatives 
within families, with appropriate genetic counselling and considerations of the ethical as-






1. Inheritable cardiac channelopathies are rare genetic disorders associated with an 
increased risk of ventricular arrhythmia and sudden death, often in previously 
asymptomatic and ostensibly healthy young individuals with a structurally normal 
heart.  
2. The common clinical endpoint of the different cardiac channelopathies is a predis-
position to development of ventricular tachyarrhythmias that results from an imbal-
ance in ionic currents of cardiac repolarisation, mainly caused by mutations in 
genes encoding ion channels and associated structures. 
3. Channelopathies are genetically heterogenous conditions with variable expressivity 
and incomplete penetrance.  
4. Genetic testing in cardiac channelopathies may have diagnostic, therapeutic and 
prognostic values, however these are very much disease-dependent. The highest 
yield is in long QT syndrome with 75-80% diagnostic confirmation of the disease, 
and may therapeutic and prognostic implications. 
5. Interpretation of genetic test results may be challenging and requires expertise.  
6. Predictive genetic testing is offered for clinically unaffected family members in a 
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Table 1. Diagnostic criteria for LQTS 
 
Criteria Points 
ECG (in the absence of condition affecting these features) 
QTc = QT / √ RR  ≥ 480ms 3 
 460 - 479 ms 2 
 450 - 459 ms (men) 1 
QTc ≥ 480ms at 4 min into recovery on exercise test  1 
Torsades de pointes VT 2 
T wave alternans 1 
Notched T waves in 3 leads 1 
Sinus bradycardia (resting HR < 2nd percentile for age) 0.5 
Clinical history   
Syncope with stress 2 
 without stress 1 
Congenital deafness 1 
Family History   
Definite LQTS 1 












Table 2. Main cardiac ion channels and their genes, contributing to currents of cardiac ac-
tion potential 
 
Current Description AP phase Type of activation Protein Gene 
Inward 
INa Na+ current phase 0 voltage, depolarisa-
tion 
NaV1.5 SCN5A 
ICa,L Ca2+ current, L-type phase 2 voltage, depolarisa-
tion 
Cav1.2 CACNA1C 




Ito,f transient outward 
current, fast 
phase 1 voltage, depolarisa-
tion 
KV 4.2/4.3 KCND2/3 
Ito,s transient outward 
current, slow 
phase 1 voltage, depolarisa-
tion 
KV 1.4/1.7/3.4 KCNA4 
KCNA7 
KCNC4 
IKur delayed rectifier, ul-
trarapid 




IKr delayed rectifier, 
fast 
phase 3 voltage, depolarisa-
tion 
HERG KCNH2 
IKs delayed rectifier, 
slow 
phase 3 voltage, depolarisa-
tion 
KVLQT1 KCNQ1 
IK1 inward rectifier phase 3,4 voltage, depolarisa-
tion 
Kir 2.2/2.2 KCNJ2/12 
IKATP ADP-activated K+ 
current 
phase 1,2 [ADP]/[ATP] ↑ Kir 6.2 KCNJ11 
IKAch Muscarinic-gated K+ 
current 
phase 4 Acetylcholine Kir 3.1/3.4 KCNJ3/5 






IF Pacemaker (funny) 
current 













Table 3. Genes associated with cardiac channelopathies 
 
Gene Locus Inheritance Protein Functional ef-fect Phenotype 
Frequency 
in disease 





AR JLN1 <1% 
KCNH2 7q36.1 AD Kv11.1 loss-of-function LQT2 25-30% 
SCN5A 3p22.2 AD Nav1.5 gain-of-func-tion LQT3 5-10% 




loss-of-function LQT5 <1% 
AR loss-of-function JLN2 <1% 
KCNE2 21q22.11 AD MiRP1 loss-of-function LQT6 <1% 
KCNJ2 17q24.3 AD Kir2.1 loss-of-function LQT7 (ATS1) <1% 
CACNA1C 12p13.33 AD Cav1.2 gain-of-func-tion LQT8 (TS1) <1% 
CAV3 3p25.3 AD Caveolin 3 gain-of-func-tion LQT9 <1% 
SCN4B 11q23.3 AD Nav β4 subunit gain-of-func-tion LQT10 <0.1% 
AKAP9 7q21.2 AD A-kinase an-chor protein 9 loss-of-function LQT11 <0.1% 
SNTA1 20q11.21 AD Syntrophin α1 gain-of-func-tion LQT12 <0.1% 
KCNJ5 11q24.3 AD Kir 3.4 subunit of IKAch channel loss-of-function LQT13 <0.1% 
CALM1 14q32.11 AD Calmodulin 1 loss-of-function LQT14 <1% 
CALM2 2p21 AD Calmodulin 2 loss-of-function LQT15 <1% 
Brugada syndrome 
SCN5A 3p22.2 AD Nav1.5 loss-of-function BrS1 20-30% 
  
Gene Locus Inheritance Protein Functional ef-fect Phenotype 
Frequency 
in disease 
GPD1-L 3p22.3 NA Glycerol-3P dh1 loss-of-function BrS2 <1% 
SCN1B 19q13.12 NA Nav β1 subunit loss-of-function BrS5 <1% 
SCN3B 11q24.1 AD Nav β3 subunit loss-of-function BrS7 <1% 
SCN2B 11q23.3 AD Nav β2 subunit loss-of-function BrS16 <1% 
CACNA1C 12p13.33 AD Cav1.2 loss-of-function BrS3 10% 
CACNB2 10p12.33-p12.31 AD 
L-type Cav β2 
subunit loss-of-function BrS4 <1% 
CACNA2D1 7q21-q22 NA L-type Cav 
α2/δ1 subunit 
loss-of-function BrS10 <1% 








 ↓ If current 
BrS8 <1% 
KCND3 1p13.2 AD Kv4.3 gain-of-func-tion BrS11 <1% 
KCNE3 11q13.4 NA MiRP2 gain-of-func-tion BrS6 <1% 
KCNE5 Xq22.3 NA Kv accessory subunit 5 
gain-of-func-
tion BrS15 <1% 
KCNJ8 12p11.23 NA Kir6.1 gain-of-func-tion BrS 9 <1% 
RANGFR 17p13.1 NA 
RAN guanine 
nucleotide re-
lease factor 1 
loss-of-function BrS12 <1% 
SLMAP 3p14.3 NA sarcolemma as-sociated protein loss-of-function BrS13 <1% 






loss-of-function BrS14 6% 
Catecholaminergic polymorphic ventricular tachycardia 
  
Gene Locus Inheritance Protein Functional ef-fect Phenotype 
Frequency 
in disease 
RYR2 1q43 AD Ryanodin re-ceptor 2 loss-of-function CPVT1 50-60% 
CASQ2 1p13.1 AR Calsequestrin 2 loss-of-function CPVT2 1-2% 
TRDN 6q22.31 AR Triadin loss-of-function CPVT5 NA 
CALM1 14q32.11 AD Calmodulin 1 loss-of-function CPVT4 <1% 
Short QT syndrome 
KCNH2 7q36.1 AD Kv11.1 gain-of-func-tion SQT1 NA 
KCNQ1 11p15.5 AD Kv7.1 gain-of-func-tion SQT2 NA 







Abbreviations: AD, autosomal dominant; AR, autosomal recessive; NA, not ascertained or applicable. 
